Figure 5.
Figure 5. Membrane translocation of type IV 5-ptase reduces plasma membrane PIP2 and releases moesin and ezrin from the membrane. (A) Jurkat cells were transfected with GFP-tagged PH domain or the indicated GFP-moesin or GFP-ezrin constructs, along with the membrane-targeted FRB-CFP and the mRFP-FKBP domain constructs (with or without type IV 5-ptase domain as indicated), and were analyzed by fluorescence microscopy before and after rapamycin (Rapa) treatment. GFP fluorescence is shown. mRFP-FKBP, mRFP-FKBP– 5-ptase, and FRB-CFP fluorescence images are shown in Fig. S1 (available). (B) Quantitative analysis of the membrane enrichment of moesin, ezrin, or PH domain constructs (n = 10 for each condition) was performed as described in Materials and methods. Error bars indicate SEM.

Membrane translocation of type IV 5-ptase reduces plasma membrane PIP2 and releases moesin and ezrin from the membrane. (A) Jurkat cells were transfected with GFP-tagged PH domain or the indicated GFP-moesin or GFP-ezrin constructs, along with the membrane-targeted FRB-CFP and the mRFP-FKBP domain constructs (with or without type IV 5-ptase domain as indicated), and were analyzed by fluorescence microscopy before and after rapamycin (Rapa) treatment. GFP fluorescence is shown. mRFP-FKBP, mRFP-FKBP– 5-ptase, and FRB-CFP fluorescence images are shown in Fig. S1 (available). (B) Quantitative analysis of the membrane enrichment of moesin, ezrin, or PH domain constructs (n = 10 for each condition) was performed as described in Materials and methods. Error bars indicate SEM.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal